Failed Experiment ReportOpen accessMedicine· cited by 118

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

Laura Evgin; Amanda L. Huff; Phonphimon Wongthida; Jill Thompson; Tim Kottke; Jason M. Tonne; Matthew Schuelke; Katayoun Ayasoufi · 2020 · Nature Communications

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

Abstract

The application of adoptive T cell therapies, including those using chimeric antigen receptor (CAR)-modified T cells, to solid tumors requires combinatorial strategies to overcome immune suppression associated with the tumor microenvironment. Here we test whether the inflammatory nature of oncolytic viruses and their ability to remodel the tumor microenvironment may help to recruit and potentiate the functionality of CAR T cells. Contrary to our hypothesis, VSVmIFNβ infection is associated with attrition of murine EGFRvIII CAR T cells in a B16EGFRvIII model, despite inducing a robust proinflam

Abstract by Laura Evgin; Amanda L. Huff; Phonphimon Wongthida; Jill Thompson; Tim Kottke; Jason M. Tonne; Matthew Schuelke; Katayoun Ayasoufi, Nature Communications (2020) — licensed CC BY 4.0.

Read the full paper (open access)